Your session is about to expire
← Back to Search
IBD for Irritable Bowel Syndrome
Study Summary
This trial will compare the microbes and peptides in inner-colonic samples from IBD patients to those from home stool samples.
- Irritable Bowel Syndrome
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there still opportunities for subjects to participate in this clinical trial?
"This research trial, which was first available for enrolment on March 16th 2022, is still looking to add new participants according to the information posted on clinicaltrials.gov and last updated on November 28th of this year."
Does the protocol for this trial allow individuals of advanced age to participate?
"To be eligible for this clinical trial, applicants must range between the ages of 18 to 80. Alternatively, there are 69 similar trials available for minors and 229 such studies for elderly individuals."
What is the upper limit of participants in this clinical trial?
"Yes, the details on clinicaltrials.gov confirm that this trial is still recruiting participants. This clinical study was initially published on March 16th 2022 and updated most recently on November 28th 2022. The research team seeks 20 willing volunteers from a single location."
What are the goals of this investigation?
"The primary outcome reported by the study sponsor, HyGIeaCare Inc., will be monitored over a course of 1 year and pertains to detecting IBD-related biomarkers in stool samples. Secondary outcomes include differential abundance analysis with false discovery rate correction, alpha diversity through 16S and meta genomics analysis, as well as beta diversity using PCoA evaluation."
What kind of individuals are best suited for this clinical trial?
"This clinical trial is recruiting 20 individuals, aged 18-80 years old, who suffer from irritable bowel syndrome (IBS). Additional requirements include a diagnosis of either Ulcerative colitis or Crohn's disease for the study arm and no active IBD symptoms/diagnosis for those in the control arm."
Share this study with friends
Copy Link
Messenger